While Bio-Techne has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
2 Healthcare Stocks to Research Further and 1 We Find Risky
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q1 Earnings Call
1 Cash-Producing Stock Worth Investigating and 2 We Turn Down
TECH Q1 Deep Dive: Biotech Weakness and Order Timing Drive Top-Line Miss
Bio-Techne (NASDAQ:TECH) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
MINNEAPOLIS , May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026.
MINNEAPOLIS , May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March...
Barchart Research What to Expect from TECH Earnings TECH Generated May 5, 2026 Current Price $56.68 EPS Estimate $$0.48 Consensus Rating Moderate Buy Average Move 6.99% Bio-Techne: Wall Street's Biotech...